What this pack is
康忻® / CONCOR® / CARDICOR is the brand name in this record; bisoprolol fumarate is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
康忻® / CONCOR® / CARDICORGeneric namebisoprolol fumarate
How this medicine works
The U.S. public label describes bisoprolol fumarate as a synthetic beta1-selective (cardioselective) adrenoceptor blocker; at higher doses its selectivity is not absolute. This mechanism helps explain the class and why a complete medicine list needs review; it cannot predict individual heart rate, blood pressure, breathing, suitability or any combination plan.
Read source: United States ↗reviewed 2026-08-23More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- 康忻® / CONCOR® / CARDICOR
- Source-scoped market brand names
- 康忻® / Concor® · Mainland China and cross-market company brand pageCompany product-page name/strength cue ↗Merck China's company page identifies 康忻®/Concor® as a bisoprolol product family. This entry is only for checking pack text and the generic-name cue; it does not establish current authorisation, holder, exact strength/package, supply, sale eligibility, authenticity or interchangeability with another bisoprolol product in any country or region.
- CONCOR / CONCOR COR · Dated authorisation list across multiple European countriesHistorical regulator record ↗The EMA's 2020 PSUSA national-authorisation list includes multiple Concor/Concor COR strengths held by Merck entities. This establishes brand and authorisation records at that dated list, not current 2026 supply, exact packaging, sale eligibility or interchangeability in any country.
- CARDICOR · UK public medicine informationSource-scoped evidence ↗The currently accessible UK emc Merck Cardicor SmPC/PIL jointly lists six film-coated tablet strengths; its content was last updated on 17 Nov 2020. It is a UK product-information route and does not replace the current label for Concor in Mainland China or another market.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- bisoprolol fumarate
- Dosage-form class
- Bisoprolol fumarate film-coated oral tablets: UK Cardicor 1.25, 2.5, 3.75, 5, 7.5 and 10 mg; U.S. repackaged label 5 and 10 mg
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
7 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (updated 20 Mar 2026; repackaged label)
5 mg and 10 mg labelled per tablet (U.S. label)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 68788-8671-1 (source NDC 29300-126)
- Form and route
- bisoprolol fumarate oral tablet · oral (label product-identity field)
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- bisoprolol fumarate
- 5 mg5 mg labelled per tablet; not an individual's tablet count, frequency or conversion instruction
- bisoprolol fumarate
- 10 mg10 mg labelled per tablet; not an individual's tablet count, frequency or conversion instruction
GB · Merck Cardicor SmPC currently accessible on UK emc (content last updated 17 Nov 2020; current supply not inferred)
Cardicor 1.25 mg per tablet (UK label text identity)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- UK eMC product 7765 shared SmPC
- Form and route
- Cardicor bisoprolol fumarate film-coated oral tablet · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- bisoprolol fumarate
- 1.25 mglabelled per tablet; not an individual's tablet count, frequency or conversion instruction
- Labelled appearance
- white · round and unscored film-coated tabletUnscored in this labelled presentation
GB · Merck Cardicor SmPC currently accessible on UK emc (content last updated 17 Nov 2020; current supply not inferred)
Cardicor 2.5 mg per tablet (UK label text identity)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- UK eMC product 7765 shared SmPC
- Form and route
- Cardicor bisoprolol fumarate film-coated oral tablet · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- bisoprolol fumarate
- 2.5 mglabelled per tablet; not an individual's tablet count, frequency or conversion instruction
- Labelled appearance
- white · heart-shaped and scored film-coated tabletScored appearance; this is not a self-splitting instruction
GB · Merck Cardicor SmPC currently accessible on UK emc (content last updated 17 Nov 2020; current supply not inferred)
Cardicor 3.75 mg per tablet (UK label text identity)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- UK eMC product 7765 shared SmPC
- Form and route
- Cardicor bisoprolol fumarate film-coated oral tablet · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- bisoprolol fumarate
- 3.75 mglabelled per tablet; not an individual's tablet count, frequency or conversion instruction
- Labelled appearance
- off-white · heart-shaped and scored film-coated tabletScored appearance; this is not a self-splitting instruction
GB · Merck Cardicor SmPC currently accessible on UK emc (content last updated 17 Nov 2020; current supply not inferred)
Cardicor 5 mg per tablet (UK label text identity)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- UK eMC product 7765 shared SmPC
- Form and route
- Cardicor bisoprolol fumarate film-coated oral tablet · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- bisoprolol fumarate
- 5 mglabelled per tablet; not an individual's tablet count, frequency or conversion instruction
- Labelled appearance
- yellowish white · heart-shaped and scored film-coated tabletScored appearance; this is not a self-splitting instruction
GB · Merck Cardicor SmPC currently accessible on UK emc (content last updated 17 Nov 2020; current supply not inferred)
Cardicor 7.5 mg per tablet (UK label text identity)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- UK eMC product 7765 shared SmPC
- Form and route
- Cardicor bisoprolol fumarate film-coated oral tablet · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- bisoprolol fumarate
- 7.5 mglabelled per tablet; not an individual's tablet count, frequency or conversion instruction
- Labelled appearance
- pale yellow · heart-shaped and scored film-coated tabletScored appearance; this is not a self-splitting instruction
GB · Merck Cardicor SmPC currently accessible on UK emc (content last updated 17 Nov 2020; current supply not inferred)
Cardicor 10 mg per tablet (UK label text identity)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- UK eMC product 7765 shared SmPC
- Form and route
- Cardicor bisoprolol fumarate film-coated oral tablet · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- bisoprolol fumarate
- 10 mglabelled per tablet; not an individual's tablet count, frequency or conversion instruction
- Labelled appearance
- pale orange to light orange · heart-shaped and scored film-coated tabletScored appearance; this is not a self-splitting instruction
PACKAGE-VISUAL STATUS
Cardicor text appearance is verified and the U.S. record is repackaged; neither is presented as an exact original-brand package image
The UK Cardicor SmPC provides colour, shape and score wording for six tablets but no public exact pack image matched one to one to a single strength and package; the U.S. DailyMed page is explicitly repackaged. To avoid treating label text, a repackaged image or another-market retail image as an exact Concor/Cardicor original-brand pack, the page uses text identity cards for appearance and strength and retains primary label links for enlarged reading.
LABEL READING · NOT A PRESCRIPTION
Concor / Cardicor label reading: first separate brand, market, mg per tablet and score status
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module links the Merck China brand family, a dated EMA authorisation list, UK emc Merck Cardicor SmPC/PIL and a U.S. repackaged generic label. It helps check brand, bisoprolol fumarate, film-coated tablet, per-tablet strength, appearance and document market; it cannot provide anyone's tablet count, timing, missed-use handling, splitting, stopping, switching or combination plan.
- Check Concor, Cardicor or the actual trade name, bisoprolol fumarate, film-coated oral tablet, mg per tablet, actual pack and target market together. A shared bisoprolol name or number does not prove that another strength, brand, beta-blocker or another-market product can be self-substituted, combined or alternated.
- The UK Cardicor SmPC jointly lists 1.25, 2.5, 3.75, 5, 7.5 and 10 mg; the U.S. repackaged label lists 5 and 10 mg. These distinguish exact tablets in their own documents, not a webpage formula for how many per day, adding strengths, changing timing or making up missed use.
- The label describes bisoprolol as a beta1-selective (cardioselective) adrenoceptor blocker and notes that this selectivity is not absolute. With heart-rate or blood-pressure concerns, breathing difficulty, fainting, marked dizziness, or a planned surgical/dental procedure, use local medical and prescribing-team channels; do not self-adjust, abruptly stop or change to another cardiovascular medicine from this page.
- The UK Cardicor SmPC says the listed scored 2.5–10 mg tablets can be divided into equal doses, but that is product-specific wording for the exact Cardicor document. It does not automatically apply to Concor, a U.S. generic or another maker's tablet, and does not mean anyone should split a tablet. Splitting requires the actual pack, current local label, prescription and pharmacist/prescriber review.
- If the list also includes metoprolol, carvedilol, digoxin, clonidine, verapamil, diltiazem, amiodarone, glucose-lowering medicines, a beta-blocker eye drop, OTC product or supplement, take every actual pack and the complete medicine list to a pharmacist or prescriber. Do not self-combine, time-separate or substitute products merely because they mention the heart, blood pressure or beta blockade.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkUK electronic medicines compendium (emc) · United Kingdom · Public product information or patient leaflet · 2026-08-30
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United Kingdom · 2
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeUK emc: Merck Cardicor 1.25–10 mg film-coated tablets SmPC (product 7765; content last updated 17 Nov 2020) ↗reviewed 2026-08-30
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- UK electronic medicines compendium (emc) · United Kingdom · Public product information or patient leaflet · 2026-08-30UK emc: Merck Cardicor patient information leaflet (product 7765) ↗reviewed 2026-08-30
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-23DailyMed (NLM): current U.S. BISOPROLOL FUMARATE public label (Preferred Pharmaceuticals; updated 20 Mar 2026; repackaged label) ↗reviewed 2026-08-23
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about 康忻® / CONCOR® / CARDICOR (bisoprolol fumarate). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
康忻® / CONCOR® / CARDICOR is the brand in this record and bisoprolol fumarate is the active-ingredient name. Check both with the dosage form (Bisoprolol fumarate film-coated oral tablets: UK Cardicor 1.25, 2.5, 3.75, 5, 7.5 and 10 mg; U.S. repackaged label 5 and 10 mg) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- UK emc: Merck Cardicor 1.25–10 mg film-coated tablets SmPC (product 7765; content last updated 17 Nov 2020) ↗reviewed 2026-08-30
- UK emc: Merck Cardicor patient information leaflet (product 7765) ↗reviewed 2026-08-30
- DailyMed (NLM): current U.S. BISOPROLOL FUMARATE public label (Preferred Pharmaceuticals; updated 20 Mar 2026; repackaged label) ↗reviewed 2026-08-23
HOW IT WORKS · NOT A TREATMENT PLAN
How bisoprolol works: beta1 selectivity explains a pathway, not an individual plan
- ‘Beta1 selectivity’ describes a relative receptor tendency; it is not a webpage conclusion that a person is definitely suitable, will definitely tolerate it, or can use it with another heart-rate/blood-pressure-related medicine. Prior reactions, respiratory history, tests, the complete medicine list and the exact product label all need professional review.
- A similar class or mechanism does not establish personal conversion, same-day combination, alternate-day use or interchangeability between bisoprolol, metoprolol, carvedilol or another beta-blocker. Name, salt, strength, dosage form, market label and prescription are all part of product identity.
- For older people or people using multiple medicines, a mechanism explanation especially cannot replace item-by-item review: bring all packs, prescription labels, OTC products and supplements, and note actual timing and symptoms for a pharmacist or prescribing team to review.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- Merck China: Concor bisoprolol product-family page ↗reviewed 2026-08-20
- EMA: dated historical list of nationally authorised bisoprolol products (PSUSA/00000419/201909) ↗Historical public record · reviewed 2026-08-20
- UK emc: Merck Cardicor 1.25–10 mg film-coated tablets SmPC (product 7765; content last updated 17 Nov 2020) ↗reviewed 2026-08-30
- UK emc: Merck Cardicor patient information leaflet (product 7765) ↗reviewed 2026-08-30
- DailyMed (NLM): current U.S. BISOPROLOL FUMARATE public label (Preferred Pharmaceuticals; updated 20 Mar 2026; repackaged label) ↗reviewed 2026-08-23
SOURCE-TRACEABLE ARCHIVE
康忻® / CONCOR® / CARDICORbisoprolol fumarate
This page links to public primary-source material for 康忻® / CONCOR® / CARDICOR. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
EMA national-authorisation list for bisoprolol
The EMA PSUSA/00000419/201909 list records multiple nationally authorised Concor, Concor COR, Cardicor and related strengths held by Merck entities. It establishes records at the document date, not current 2026 supply, exact packaging, sale eligibility, authenticity or interchangeability in any country.
EMA: list of nationally authorised bisoprolol products (PSUSA/00000419/201909) ↗UK Cardicor SmPC content-update node
The UK emc Merck Cardicor SmPC jointly lists 1.25, 2.5, 3.75, 5, 7.5 and 10 mg film-coated tablets, appearance and score wording. The page remained publicly accessible on 30 Aug 2026, but its content was last updated on 17 Nov 2020; this dossier therefore treats it as dated UK product information, not live stock or a globally uniform label.
UK emc: Merck Cardicor 1.25–10 mg film-coated tablets SmPC ↗Current U.S. DailyMed public label updated
DailyMed lists 20 Mar 2026 as the Updated date for this BISOPROLOL FUMARATE oral-tablet public label, identifies Preferred Pharmaceuticals Inc. as packager, and explicitly marks it repackaged. This node only locates the U.S. label for 5 mg/10 mg tablets, NDC 68788-8671-1 and source NDC 29300-126; it does not establish an original brand, actual availability, stock, purchase, individual tablet count, splitting, co-use or switching.
DailyMed (NLM): current U.S. BISOPROLOL FUMARATE public label (Preferred Pharmaceuticals; updated 20 Mar 2026; repackaged label) ↗
MARKET SCOPE
Market-record boundary
United States
Current repackaged public label linked; not displayed as an original-brand packageThis page links only the U.S. label's bisoprolol fumarate 5 mg/10 mg oral tablets, NDC 68788-8671-1 and source NDC 29300-126. Although the label contains a package image, it is explicitly repackaged and is not used here as original-brand appearance; it also does not establish actual availability, stock, purchase, authenticity, individual tablet count, frequency, stopping, switching or interchangeability.
Mainland China brand cue
Merck China Concor brand-family page linked; current authorisation and packaging still require regulatory recordsThe Merck China company page confirms the relationship between Concor and the bisoprolol product family, but a company brand page does not replace a current approved label or establish exact packaging, supply or sale eligibility.
Dated UK and European material
Cardicor SmPC/PIL and EMA national-authorisation list linkedThe page builds text identity cards for six Cardicor film-coated tablets and links the dated EMA national-authorisation list. Each source provides brand, strength, appearance or authorisation cues only within its own document scope; neither proves real-time 2026 supply or cross-market substitution.
Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from Chinese, UK, EMA or U.S. material; every market requires separate checking against current local regulatory information.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
The label has 5 mg and 10 mg. Can I adjust myself by splitting, adding strengths or switching to another beta-blocker?
No. 5 mg and 10 mg are identity fields for exact tablets in this U.S. label; they do not establish individual tablet count, splitting, make-up use, adjustment, same-day combination, alternate-day use or conversion with another beta-blocker. Take the actual pack, current prescription and complete medicine list to a pharmacist or prescribing team for review.
The UK Cardicor label says scored tablets can be divided equally. Can I apply that to my Concor or bisoprolol tablet?
Do not carry that wording across products. It applies only to the exact tablets listed in the UK Cardicor document; the prescription, functional score, excipients, tablet design and local label may differ for Concor, a U.S. generic or another maker. Splitting requires confirmation using the actual pack, current local label, prescription and pharmacist/prescriber review.
Why does the page not display the package photo in this U.S. label?
This DailyMed page is explicitly identified as a repackaged label. To avoid reading a repackaged image as an originator, original-brand or another-market exact appearance, this page retains the readable primary-label link but does not display that image as an original-brand package.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.